NO20015059L - HCV-kombinasjonsterapi, inneholdende ribavirin i assosiasjon med antioksydanter - Google Patents

HCV-kombinasjonsterapi, inneholdende ribavirin i assosiasjon med antioksydanter

Info

Publication number
NO20015059L
NO20015059L NO20015059A NO20015059A NO20015059L NO 20015059 L NO20015059 L NO 20015059L NO 20015059 A NO20015059 A NO 20015059A NO 20015059 A NO20015059 A NO 20015059A NO 20015059 L NO20015059 L NO 20015059L
Authority
NO
Norway
Prior art keywords
antioxidants
association
combination therapy
hcv combination
containing ribavirin
Prior art date
Application number
NO20015059A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015059D0 (no
Inventor
Clifford A Brass
Paul W Glue
Edward Piken
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20015059D0 publication Critical patent/NO20015059D0/no
Publication of NO20015059L publication Critical patent/NO20015059L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20015059A 1999-04-19 2001-10-18 HCV-kombinasjonsterapi, inneholdende ribavirin i assosiasjon med antioksydanter NO20015059L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29468799A 1999-04-19 1999-04-19
PCT/US2000/010240 WO2000062799A1 (fr) 1999-04-19 2000-04-18 Polytherapie de l'hepatite c utilisant de la ribavirine associee a des anti-oxydants

Publications (2)

Publication Number Publication Date
NO20015059D0 NO20015059D0 (no) 2001-10-18
NO20015059L true NO20015059L (no) 2001-12-19

Family

ID=23134504

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015059A NO20015059L (no) 1999-04-19 2001-10-18 HCV-kombinasjonsterapi, inneholdende ribavirin i assosiasjon med antioksydanter

Country Status (14)

Country Link
EP (1) EP1046399A1 (fr)
JP (1) JP2002542202A (fr)
CN (1) CN1355708A (fr)
AR (1) AR023541A1 (fr)
AU (1) AU4463300A (fr)
BR (1) BR0009840A (fr)
CA (1) CA2306039A1 (fr)
CO (1) CO5241354A1 (fr)
HU (1) HUP0200942A3 (fr)
MX (1) MXPA00003974A (fr)
NO (1) NO20015059L (fr)
PE (1) PE20010284A1 (fr)
WO (1) WO2000062799A1 (fr)
ZA (1) ZA200108571B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
SK11922002A3 (sk) 2000-02-18 2003-06-03 Shire Biochem Inc. Použitie analógov nukleozidov na liečenie alebo prevenciu infekcií spôsobených flavivírusom
IL155730A0 (en) 2000-11-03 2003-11-23 Biomedicines Inc Method for short-term and long-term drug dosimetry
ITMI20011863A1 (it) * 2001-09-05 2003-03-05 Zambon Spa Associazione di farmaci contro il virus dell'influenza
WO2003024461A1 (fr) * 2001-09-20 2003-03-27 Schering Corporation Polytherapie de l'hepatite c
US20040022873A1 (en) * 2001-11-09 2004-02-05 Guilford F. Timothy Systemic administration of NAC as an adjunct in the treatment of bioterror exposures such as anthrax, smallpox or radiation and for vaccination prophylaxis, and use in combination with DHEA for the treatment of smallpox and other viruses
ATE353658T1 (de) * 2002-06-03 2007-03-15 Nat Health Research Institutes Behandlung von flavivirusinfizierungen
WO2004050101A2 (fr) * 2002-11-29 2004-06-17 Gpc Biotech Ag Formulations utiles pour lutter contre les infections par le virus de l'hepatite c
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP4570563B2 (ja) * 2003-02-21 2010-10-27 持田製薬株式会社 リバビリン／インターフェロン併用療法の副作用軽減剤
CN1835765A (zh) * 2003-08-13 2006-09-20 霍华德·J·史密斯及同仁控股有限公司 治疗病毒感染的方法
WO2005120479A1 (fr) * 2004-06-09 2005-12-22 Gpc Biotech Ag Utilisation de selenium ou d'un sel de selenium et d'un acide retinoique ou d'un retinoide pour traiter une hepatite c virale
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (fr) 2005-02-03 2006-08-10 Alza Corporation Solutions de solvant/polymere utilisees comme vehicules de suspension
EP2020990B1 (fr) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Modulateur de flux en deux pieces avec conduit interne pour un assemblage d'administration osmotique.
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
EP2157967B1 (fr) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Formulations en suspension de peptides insulinotropes et leurs utilisations
EP2240155B1 (fr) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Dispositifs, formulations et méthodes d administration de plusieurs agents bénéfiques
EP3323423B1 (fr) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Établissement rapide et/ou arrêt rapide d'une administration constante substantielle de médicament
MX380504B (es) 2010-06-03 2025-03-12 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20130129680A1 (en) * 2011-11-23 2013-05-23 Thomas Christian Lines Method for treating hepatitis c virus infection using quercetin-containing compositions
HK1206073A1 (en) 2012-07-24 2015-12-31 药品循环有限责任公司 Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
SG11201503459SA (en) 2012-11-02 2015-06-29 Pharmacyclics Inc Tec family kinase inhibitor adjuvant therapy
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
KR20240037175A (ko) 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5157998A (en) * 1996-11-01 1998-05-29 Thomas Najarian Methods and compositions for treatment of hepatitis c infection

Also Published As

Publication number Publication date
ZA200108571B (en) 2003-01-20
MXPA00003974A (es) 2002-03-08
CN1355708A (zh) 2002-06-26
BR0009840A (pt) 2002-01-08
JP2002542202A (ja) 2002-12-10
CA2306039A1 (fr) 2000-10-19
AU4463300A (en) 2000-11-02
PE20010284A1 (es) 2001-03-05
NO20015059D0 (no) 2001-10-18
WO2000062799A1 (fr) 2000-10-26
AR023541A1 (es) 2002-09-04
HUP0200942A2 (hu) 2002-07-29
CO5241354A1 (es) 2003-01-31
HUP0200942A3 (en) 2003-03-28
EP1046399A1 (fr) 2000-10-25

Similar Documents

Publication Publication Date Title
NO20015059D0 (no) HCV-kombinasjonsterapi, inneholdende ribavirin i assosiasjon med antioksydanter
EE04528B1 (et) Teraapias kasutatavad spirofuropridiinide aralklamiinid
PT1157023E (pt) Epotilonas modificadas em c-21
AR028622A1 (es) Derivados de tropano utiles en terapia
DE69904016D1 (de) Laminatformkörper
PT1060695E (pt) Cadeira empilhavel
NO20014490D0 (no) Medisinske blandinger
DE60022254D1 (de) Verbesserungen in Reifen
DK0903130T4 (da) Forbedringer i forbindelse med ostomiindretninger
IL165521A0 (en) Interferon-beta in HCV
NO20021976L (no) Selektiv leverterapi
IT1310385B1 (it) Dispositivo per migliorare la respirazione.
DE50009602D1 (de) Absorptionskühlanordnung
DE50004514D1 (de) Signalisierungsverfahren im rach-kanal
NO20030214D0 (no) CRF2 ligander i kombinasjonsterapi
NO992607D0 (no) System med sÕrhelende virkning
DK1065098T3 (da) Arrangement i lastrum
ES1044373Y (es) Percha con bolsa incorporada perfeccionada.
NO991170D0 (no) Anordning i forbindelse med supplementµre tjenester
NO991343D0 (no) Anordning i forbindelse med supplementµre tjenester
TW435091U (en) Underpants with dividing structure
DE50003427D1 (de) Rinnenkörper
FI990112A0 (fi) Lehmän poikimavahti
BR7902842Y1 (pt) disposiÇço introduzida em quadro de distribuiÇço.
ES1044603Y (es) Preservativo perfeccionado.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application